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Abstract
Background: The objective of this study was to estimate the number of years after onset of a 
quadrivalent HPV vaccination program before notable reductions in genital warts and cervical 
intraepithelial neoplasia (CIN) will occur in teenagers and young adults in the United States.
Methods: We applied a previously published model of HPV vaccination in the United States and 
focused on the timing of reductions in genital warts among both sexes and reductions in CIN 2/3 
among females. Using different coverage scenarios, the lowest being consistent with current 3-
dose coverage in the United States, we estimated the number of years before reductions of 10%, 
25%, and 50% would be observed after onset of an HPV vaccination program for ages 12–26 
years.
Results: The model suggested female-only HPV vaccination in the intermediate coverage 
scenario will result in a 10% reduction in genital warts within 2–4 years for females aged 15–19 
years and a 10% reduction in CIN 2/3 among females aged 20–29 years within 7–11 years. 
Coverage had a major impact on when reductions would be observed. For example, in the higher 
coverage scenario a 25% reduction in CIN2/3 would be observed with 8 years compared with 15 
years in the lower coverage scenario.
Conclusions: Our model provides estimates of the potential timing and magnitude of the impact 
of HPV vaccination on genital warts and CIN 2/3 at the population level in the United States. 
Notable, population-level impacts of HPV vaccination on genital warts and CIN 2/3 can occur 
within a few years after onset of vaccination, particularly among younger age groups. Our results 
are generally consistent with early reports of declines in genital warts among youth.
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1. Introduction
Human papillomavirus (HPV) vaccination is expected to reduce the burden of HPV-
associated disease in the United States [1]. However, mathematical modeling studies have 
suggested that reductions in HPV-associated cancers could take decades to achieve through 
vaccination [2–9]. In contrast, notable reductions in genital warts and high grade cervical 
intraepithelial neoplasia (CIN) are expected to occur much sooner after onset of HPV 
vaccination than the reductions in HPV-associated cancers [5–7]. As such, plans to monitor 
vaccine impact in the United States and other developed countries include HPV-associated 
outcomes with shorter expected time frames to observe vaccine impact (such as CIN and 
genital warts) in addition to longer-term outcomes such as cervical cancer [10,11]. In fact, 
there is preliminary, ecological evidence of a population-level impact of HPV vaccine on 
genital warts and high-grade cervical abnormalities among teenagers and young adults in the 
United States and Australia [12–17].
The purpose of this project was to estimate the number of years after onset of a quadrivalent 
HPV vaccination program before notable reductions in CIN 2/3 and genital warts will occur 
among teenagers and young adults in the United States. These estimates can help to illustrate 
plausible scenarios of HPV vaccine impact over time.
2. Methods
2.1. Description of model
We used a deterministic, dynamic population-based HPV model to estimate the timing of 
reductions in genital warts and CIN 2/3 after onset of quadrivalent HPV vaccination in the 
United States [6]. The model, described in more detail elsewhere [6], is a simplified 
compartmental model in which each age cohort was divided into four classes (“susceptible, 
not vaccinated”; “infected, not vaccinated”, “vaccinated, not infected”, and “vaccinated, 
infected”) according to type-specific HPV infection. Specifically, the model calculations 
were performed separately for HPV 16, HPV 18, and HPV 6/11, and the impact of 
quadrivalent vaccination was estimated based on the combined results of these calculations.
The model first takes into account the incidence of HPV-associated health outcomes in the 
absence of HPV vaccination, obtained primarily from surveillance data and medical claims 
data. Then, reductions in the incidence of these adverse outcomes are estimated based on 
vaccine coverage, vaccine efficacy, and the percentage of the adverse health outcomes 
attributable to the HPV vaccine types. To do so, we apply annual, sex- and age-specific 
probabilities of acquiring a specific HPV type. Vaccination is assumed to reduce the annual 
probability of acquiring HPV vaccine types according to the vaccine efficacy assumptions 
below. To reflect indirect effects of vaccination (herd immunity), these sex and age-specific 
HPV acquisition probabilities are adjusted each year to reflect reductions in HPV in the 
population. Rather than explicitly modeling the transition from HPV acquisition to HPV-
associated outcomes, we estimate vaccine impact by assuming the percentage reduction in 
health outcomes attributable to a given HPV type was equal to the percentage reduction in 
cumulative lifetime exposure to that HPV type.
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In this study, we applied the model exactly as described previously [6], with three 
exceptions. First, we used different (updated) coverage scenarios as described in Table 1. 
Second, we modified the sensitivity analyses as described in Table 2 to focus on different 
scenarios of vaccine impact over time. Finally, we applied lower values of the annual 
probability of acquiring HPV 6/11 for ages 10–14 years so that the burden of HPV 6/11 in 
this age group relative to that of ages 15–19 years would be consistent with the 
corresponding relative burden of genital warts for these two age groups based on insurance 
claims data [18].
2.2. Time horizon
We examined the first 25 years of a vaccine program. In each year, a new cohort of 8-year-
olds entered the model and a cohort of 99-year-olds exited the model. In each year, those 
aged 12–26 years who were eligible for vaccination but who had not been vaccinated 
previously were subject to the annual probability of receiving the vaccine.
2.3. Vaccine characteristics and coverage
Vaccine efficacy against HPV 6, 11, 16, and 18 was assumed to be 95% in females and 90% 
in males [19–24], with lifelong duration of efficacy. We assumed no cross-protection against 
other, non-vaccine HPV types.
We assumed that all those who initiated the vaccine series would receive all three doses. We 
examined three coverage scenarios: lower, intermediate, and higher (Table 1). In the 
intermediate coverage scenario, the annual probability of receiving the 3-dose vaccine series 
was 28% at age 12, 17% for ages 13–18 years, and 2% for ages 19–26 years. The annual 
probabilities of receiving vaccination for the lower and intermediate scenarios were selected 
such that the resulting coverage after the first few years of the vaccine program would be 
consistent with estimates of vaccine coverage in the United States. Specifically, under the 
coverage assumptions described in Table 1, the average coverage of 13- to 17-year-olds in 
year 6 of the vaccine program would be about 37% in the lower coverage scenario and about 
52% in the intermediate coverage scenario, consistent with estimated HPV vaccine coverage 
rates of 35% (three doses) and 53% (vaccine initiation) of females aged 13–17 years in the 
United States based on 2011 data from the National Immunization Survey-Teen [25]. The 
higher coverage scenario was included to illustrate the potential impact of HPV vaccination 
when coverage of targeted age groups exceeds 70%, as has been achieved among females in 
the United Kingdom and Australia [16,26–28].
We examined six vaccination scenarios in which the three coverage levels described above 
(lower, intermediate, and higher) were applied to each of two vaccination strategies 
(vaccination of females aged 12–26 years, and vaccination of both sexes aged 12–26 years). 
When we included male vaccination, we assumed that male vaccination would begin 5 years 
after female vaccination, as the recommendation for routine HPV vaccination of males in the 
United States was established about 5 years after the recommendation for routine 
vaccination of females [29]. After onset of male vaccination, the annual probability of 
vaccination for males was assumed to be the same as females (Table 1), except in the lower 
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coverage scenario in which the annual probability of vaccination for males was assumed to 
be one-half that of females.
2.4. Assessment of vaccine impact on genital warts and high grade CIN over time
We estimated the reductions in genital warts over time among two age groups (15–19 years 
and 20–29 years) separately for both sexes. We estimated the reductions in CIN 2/3 among 
women in one age group (20–29 years). In each year of our model, the makeup of the age 
groups change as the oldest birth cohort ages out and a younger birth cohort ages in. For 
example, at the end of each year the cohort of 19-year-olds turns 20 years old, leaves the 15- 
to 19-year age group, and joins the 20- to 29-year age group. Similarly, at the end of each 
year, the 14-year-old cohort turns 15 years old and enters the 15- to 19-year age group.
2.5. Sensitivity analyses
We examined how the model results changed when we simultaneously varied several key 
assumptions in the model. In order to summarize the most extreme model results across 
various scenarios, we examined an optimistic scenario and a pessimistic scenario in which 
we simultaneously varied five key parameters as described in Table 2. In the optimistic 
scenario, values for the five parameters which maximized the estimated impact of 
vaccination were selected. Specifically, in the optimistic scenario we applied upper-bound 
values for vaccine efficacy and the percent of health outcomes attributable to the HPV 
vaccine types. We also assumed a later age at which HPV incidence peaks. In our model, 
vaccine impact (in terms of the percent decrease in genital warts and CIN among younger 
age groups) is greater when the peak age of HPV acquisition is later because a higher 
percent of those vaccinated will be naïve to the HPV vaccine types at the time of 
vaccination. In contrast, for the pessimistic scenario, we applied lower-bound values for 
vaccine efficacy and the percent of health outcomes attributable to the HPV vaccine types, 
and assumed that HPV incidence peaks at a younger age. We examined the optimistic and 
pessimistic scenarios under all three of the coverage scenarios described in Table 1.
3. Results
Reductions in selected HPV-associated outcomes over the first 25 years of the HPV vaccine 
program are shown in Figs. 1–3. Results are also summarized in Table 3, which shows the 
number of years after onset of HPV vaccination until certain thresholds of vaccine impact 
(reductions in genital warts and CIN 2/3 of at least 10%, 25%, and 50%) are observed in the 
selected age groups. The results in parentheses in Table 3 are those from the sensitivity 
analyses and show how the time frame changes under the assumptions in the optimistic and 
the pessimistic scenarios, respectively.
Of the outcomes and age groups we examined, the earliest impact of HPV vaccination was 
found for genital warts among ages 15–19 years. For example, in the intermediate coverage 
scenario, female-only vaccination was predicted to reach the threshold of a 10% reduction in 
genital warts in females aged 15–19 years within 2 years of onset of vaccination and to reach 
the threshold of a 25% reduction within 4 years (Fig. 1 and Table 3). Also in the 
intermediate coverage scenario, reductions of 10% in genital warts in males aged 15–19 
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years were predicted within 5 years under a female-only vaccination program (Fig. 2 and 
Table 3). Reductions of 10% in CIN 2/3 among women aged 20–29 years were predicted 
within 9 years in the intermediate coverage scenario (Fig. 3 and Table 3).
As expected, reductions of 25–50% in these outcomes will take longer to occur than 
reductions of 10%, just as reductions in the lower coverage scenario will take longer to 
achieve than equivalent reductions in the higher coverage scenario (Figs. 1–3 and Table 3). 
For some of the outcomes we examined, reductions of 25% and 50% were not reached over 
the 25-year analytic horizon of the model. For example, 50% reductions in CIN 2/3 among 
women aged 20–29 years were not predicted to be achieved over the 25-year analytic 
horizon in the lower coverage scenario with female-only vaccination. As another example, in 
the pessimistic scenario, reductions of 25% in genital warts in males aged 15–19 years were 
not predicted to be achieved over the 25-year analytic horizon in the lower and intermediate 
coverage scenarios for female-only vaccination.
3.1. Sensitivity analyses: optimistic and pessimistic scenarios
The degree to which results in the optimistic scenario differed from those of the pessimistic 
scenario varied across the health outcomes and age groups that we examined. For example, 
in the intermediate coverage scenario for female-only vaccination, there was little difference 
across the optimistic and pessimistic scenarios regarding the timing of reductions of 10% in 
genital warts in females aged 15–19 years. Reductions of 10% in genital warts were 
expected within 2 years in the optimistic scenario and within 4 years in the pessimistic 
scenario. In contrast, in this same intermediate-coverage scenario for female-only 
vaccination, there were substantial differences across the optimistic and pessimistic 
scenarios regarding the timing of reductions of 50% in genital warts in males aged 20–29 
years. Such reductions in genital warts were predicted within 15 years in the optimistic 
scenario but not within 25 years in the pessimistic scenario.
4. Discussion
Typically, post-licensure vaccine monitoring in the United States includes the assessment of 
vaccine coverage and implementation, monitoring vaccine safety, and evaluation of the 
vaccine’s impact on disease outcomes [11]. Current plans for monitoring the impact of HPV 
vaccine on health outcomes include the following outcomes: HPV-associated cancers, 
CIN2/3 and adenocarcinoma in situ (AIS), Pap test abnormalities, non-cervical precancer 
lesions, genital warts, and HPV prevalence [11,30,31]. As expected, our estimates suggest 
that HPV vaccine coverage is an important determinant of the timing and magnitude of the 
population-level impact of vaccination.
Although we assumed that all those who initiated vaccination would complete the series, in 
reality the completion rate among those who start the vaccine series is about 70% [25]. Our 
lower coverage scenario is consistent with 3-dose HPV vaccine coverage among females in 
the United States and our intermediate coverage scenario is consistent with ≥ 1-dose 
coverage, based on estimated vaccine coverage in 2011 [25]. Thus, if there is high vaccine 
efficacy with less than 3 doses [32], our intermediate coverage scenario might be the most 
Chesson et al. Page 5
Vaccine. Author manuscript; available in PMC 2019 September 05.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
applicable of our three scenarios in predicting the timing of HPV vaccine impact in the 
United States, at least in the short term.
4.1. Limitations
Our model is relatively simple compared to other models that have estimated the potential 
impact of HPV vaccination on various HPV-associated health outcomes [7,33–36], as 
discussed in more detail elsewhere [6]. One key simplification is that we assumed 100% 
lifelong, type-specific natural immunity against re-infection. All else equal, the estimated 
impact of HPV vaccination is generally greater in models with lower levels of natural 
immunity than in models such as ours with higher levels of natural immunity [36]. Similarly, 
the impact of HPV vaccination would be more substantial and might be observed sooner 
than we estimated if there is cross-protection against non-vaccine HPV types.
Another key simplification is that our model assesses the impact of vaccination over a 
sequence of discrete, 1-year time steps instead of continuously as in most of the more 
complex models. Our use of discrete time steps might underestimate the speed and degree to 
which HPV vaccination might impact HPV transmission dynamics, particularly in the first 
few years after vaccination. Therefore the application of our model, which was developed to 
assess the cost-effectiveness of vaccination over a 100-year time horizon, to short-term 
scenarios might lead us to over-estimate the time needed to achieve notable, population 
level-reductions in HPV-associated health outcomes.
Finally, we estimated the potential impact of HPV vaccination on the incidence of genital 
warts and CIN 2/3 assuming that all other factors that influence these outcomes (e.g., sexual 
behavior, cervical cancer screening, and availability of prevention resources) remained 
constant over time. Given the simplifications described above, our model results are best 
interpreted as a somewhat conservative illustration of possible post-vaccination impact in the 
United States and allow comparisons across different coverage scenarios.
4.2. Comparison to early reports of vaccine impact
Although our modeling predictions cannot be interpreted as precise estimates, it is useful to 
compare our modeling results with post-vaccination surveillance data to assess the 
plausibility of our model predictions. Our results are generally consistent with early reports 
of a potential population-level vaccine impact on genital warts in the United States. Based 
on medical claims data in the United States, Flagg et al. reported declines in genital warts 
prevalence of about 38% among females aged 15–19 years from 2006 to 2010 [13]. Our 
model predicted declines in genital warts among females aged 15–19 years of 25% within 4 
years (and 50% within 7 years) of female-only vaccination in the intermediate coverage 
scenario. Based on administrative claims data in California, where 1-dose HPV vaccine 
coverage among adolescent females aged 13–17 years was 56% in 2010, reductions in 
genital warts from 2007 to 2010 were estimated at 35% for females under age 21 years, 19% 
for males under age 21 years, 10% for females aged 21–25 years, and 11% for males aged 
21–25 years [12]. For the intermediate coverage scenario and higher coverage scenario, our 
model results are reasonably consistent with these estimated reductions in genital warts, at 
least among females.
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Our results are not as consistent with early reports of a potential population-level vaccine 
impact on genital warts in Australia. Donovan et al. reported declines in genital warts of 
about 60% among vaccine-eligible females (ages 12–26) within 3 years of onset of an HPV 
vaccination that achieved 70% 3-dose coverage in school-based programs [16]. Read et al. 
reported declines in genital warts of about 90% among males and females under age 21 
years within 5 years of onset of HPV vaccination, with smaller declines among men and 
women aged 21–29 years [15]. Our model does not predict reductions in genital warts of 
90% in the younger age groups within 5 years after female-only HPV vaccination. However, 
under the most optimistic assumptions in the higher coverage scenario for female-only 
vaccination, our model does predict substantial reductions in genital warts among both sexes 
within 6 years of onset of a vaccination program. For example, our model shows possible 
reductions of 50% within 2 years for females aged 15–19 years, within 6 years for males 
aged 15–19 years, and within 5 years for females aged 20–29 years, and reductions of 25% 
for males aged 20–29 years within 6 years (Table 3, higher coverage scenario, lower bound 
values).
Summary
Our model provides useful, potentially conservative estimates of the potential timing and 
magnitude of the impact of HPV vaccination on genital warts and CIN 2/3 at the population 
level in the United States. Our results are generally consistent with early reports of declines 
in genital warts among youth after onset of HPV vaccination programs, particularly if there 
is vaccine efficacy with less than a full 3-dose series.
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Fig. 1. 
The estimated decline in genital warts among females aged 15–19 years following onset of a 
quadrivalent HPV vaccination program under 6 vaccination scenarios. Two vaccination 
strategies (“Female-only vaccination” shown with solid lines and “Male and female 
vaccination” shown with dashed lines) for ages 12–26 years were modeled under three 
coverage levels (lower, intermediate, and higher) as described in Table 1.
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Fig. 2. 
The estimated decline in genital warts among males aged 15–19 years following onset of a 
quadrivalent HPV vaccination program under 6 vaccination scenarios. Two vaccination 
strategies (“Female-only vaccination” shown with solid lines and “Male and female 
vaccination” shown with dashed lines) for ages 12–26 years were modeled under three 
coverage levels (lower, intermediate, and higher) as described in Table 1.
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Fig. 3. 
The estimated decline in cervical intraepithelial neoplasia (CIN) 2/3 among females aged 
20–29 years following onset of a quadrivalent HPV vaccination program under 6 vaccination 
scenarios. Two vaccination strategies (“Female-only vaccination” shown with solid lines and 
“Male and female vaccination” shown with dashed lines) for ages 12–26 years were 
modeled under three coverage levels (lower, intermediate, and higher) as described in Table 
1.
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Table 1
Vaccine coverage scenarios: annual probability of initiating HPV vaccine series among females, by age.
Coverage scenario Age 12 years Ages 13–18 years Ages 19–26 years
Lower 0.20 0.10 0.01
Intermediate 0.28 0.17 0.02
Higher 0.70 0.60 0.35
The annual probabilities of vaccination reflect the probability of receiving all three vaccine doses among females not vaccinated in previous years. 
The probabilities shown above for vaccination at age 12 years were applied in every year of the vaccine program except year 1. In year 1, the 
probability of initiating the vaccine series at age 12 was reduced by 50% to allow for phase-in of the vaccine program. In scenarios of male 
vaccination, we applied the same annual probabilities of vaccination for males as females, except in the lower coverage scenario in which we 
assumed the probabilities of vaccination for males would be one-half that of females. A complete description of the model and a full description of 
all model parameter values and references are available elsewhere [6].
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